Research

Hormonal

Testosterone therapy (TTh) combined with GLP-1 receptor agonists (GLP-1RAs) and lifestyle modifications constitutes a comprehensive standard of care for obese men with functional hypogonadism, addressing metabolic, vascular, sexual, cognitive, and skeletal health.

For obese men with low testosterone, combining testosterone therapy with GLP-1RA medications (like semaglutide or liraglutide) and lifestyle changes (diet and exercise) is the most effective strategy. This approach not only boosts testosterone but also improves metabolic health, sexual function, and bone density, offering a comprehensive solution to obesity-related hormonal issues.

GoodSupportsHIGH confidence
This focused review article aims to present a comprehensive update on the latest data concerning combining testosterone therapy with contemporary anti-obesity pharmacotherapy as a new standard of care for obese men with functional hypogonadism, uniting metabolic, vascular, sexual, cognitive, and skeletal benefits within a comprehensive strategy to fortify corporeal resilience and enhance quality of life.
Kristina Groti Antonić et al. · The Aging Male · 2025

Why this rating

Based on a comprehensive review of multiple clinical studies, meta-analyses, and guidelines, though it is a review article rather than a single RCT.

Source

The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems

Kristina Groti Antonić et al. · The Aging Male · 2025

DOI 10.1080/13685538.2025.2601423

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →